Menu
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€15.10

€15.10

26.890%
3.2
26.890%
€30.95
 
13.08.26 / Frankfurt WKN: A0NBFF / Symbol: OMER / Name: Omeros / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Omeros Corp. Stock

A very strong showing by Omeros Corp. today, with an increase of €3.20 (26.890%) compared to yesterday's price.
Omeros Corp. is currently one of the favorites of our community with 20 Buy predictions and no Sell predictions.
As a result the target price of 30 € shows a very positive potential of 98.68% compared to the current price of 15.1 € for Omeros Corp..
For the coming years our community has positive and negative things to say abot the Omeros Corp. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Non-cyclic/Cyclic" there were negative voices in the community.

Pros and Cons of Omeros Corp. in the next few years

Pros
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
S********** s********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Omeros Corp. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Omeros Corp. 26.890% 41.784% 71.982% 317.588% 11.852% 287.378% 16.288%
Heron Therapeutics Inc. -2.820% -30.549% -20.492% -75.000% -73.878% -80.470% -96.894%
Evolus Inc -0.400% 26.997% 21.713% 31.358% 27.743% -21.775% -21.775%
Rhythm Pharmaceuticals -0.990% 5.820% 6.383% 23.457% 6.952% 309.836% 754.701%

Comments

Omeros (OMER) had its "buy" rating reaffirmed by HC Wainwright.
Ratings data for OMER provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 111.54%
Target price 29.017
Change
Ends at 26.06.27

Omeros (OMER) had its price target lowered by HC Wainwright from $40.00 to $33.00. They now have a "buy" rating on the stock.
Ratings data for OMER provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 67.99%
Target price 34.636
Change
Ends at 10.06.27

Omeros (OMER) had its "buy" rating reaffirmed by HC Wainwright. They now have a $40.00 price target on the stock.
Ratings data for OMER provided by MarketBeat
Show more

News

Omeros Q2 Earnings Call HighlightsPhoto, wide shot, wide-angle lens, soft focus,  Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-pKgbwxVSbyTCu0UzPNe8NL8D.png?st=2023-05-04T16%3A02%3A58Z&se=2023-05-04T18%3A02%3A58Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T12%3A13%3A51Z&ske=2023-05-05T12%3A13%3A51Z&sks=b&skv=2021-08-06&sig=%2BhYssNp3W0HiZMxCV64XVELyP8stYUjFhgUVfPrTLyg%3D
Omeros Q2 Earnings Call Highlights

Key Points

Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?: https://cdn.content.foolcdn.com/images/1umn9qeh/production/2d10dfb318519977a677bcb00f3da6d28e64e4b0-1200x800.png?w=800&q=75&fit=max&auto=format
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?

Choosing between Heartflow (NASDAQ:HTFL) and Omeros (NASDAQ:OMER) in 2026 requires balancing the rapid revenue growth of an AI diagnostic platform against the high-stakes commercial launch of a new

NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?: https://cdn.content.foolcdn.com/images/1umn9qeh/production/2d10dfb318519977a677bcb00f3da6d28e64e4b0-1200x800.png?w=800&q=75&fit=max&auto=format
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?

Deciding between NovoCure (NASDAQ:NVCR) and Omeros (NASDAQ:OMER) requires a look at two different stages of medical innovation. Both companies aim to solve difficult health challenges using unique